Last week, NICE echoed its earlier position on the Alzheimer’s drug lecenamab and advised that the benefits of donanemab did not, based on current evidence outweigh the costs of making it available on the NHS concluding that ‘The costs of providing donanemab, including regular infusions and intensive monitoring for serious side effects, balanced against the […]
